Share This Article:

Effects of long-term monotherapy with glimepiride vs glibenclamide on glycemic control and macrovascular events in Japanese Type 2 diabetic patients

Abstract Full-Text HTML Download Download as PDF (Size:233KB) PP. 33-37
DOI: 10.4236/jdm.2014.41006    3,919 Downloads   5,837 Views   Citations


We investigated whether long-term glimepiride (GP) monotherapy improves insulin resistance and exerts a beneficial effect on beta cell function, as compared with glibenclamide (GC). One hundred Japanese Type 2 diabetic patients were randomly assigned to the GP (n = 50) or the GC (n = 50) group. During a 5-year monitoring period, patients received the indicated SU monotherapy, while changes in SU doses were allowed as needed to maintain HbA1C below 7.0%. The GC group, in parallel with fasting insulin, showed a rapid homeostatic model assessment (HOMA)-R increase and maintained a high HOMA-R level. In contrast, HOMA-R in the GP group decreased continuously, from 2.9 at baseline to 1.8 at study completion. In the GC group, HOMA-b was markedly increased in the first 6 months, then gradually decreased through 18 months. While the HOMA-β elevation in the GP group was more moderate than that in the GC group, HOMA-β levels were maintained with a slight decrease. The cumulative macrovascular disease outcome was 1 for the GP and 7 for the GC group, showing a significant difference. These results suggest that glimepiride monotherapy markedly improved HOMA-R with moderate insulin stimulation, which may account for the difference in macrovascular disease development as compared with the group receiving glibenclamide.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Onuma, H. , Inukai, K. , Watanabe, M. , Sumitani, Y. , Hosaka, T. and Ishida, H. (2014) Effects of long-term monotherapy with glimepiride vs glibenclamide on glycemic control and macrovascular events in Japanese Type 2 diabetic patients. Journal of Diabetes Mellitus, 4, 33-37. doi: 10.4236/jdm.2014.41006.


[1] Rosak, C. (2002) The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. Journal of Diabetes and its Complications, 16, 123-132. 1016/S1056-8727(01)00207-0
[2] Rosenstock, J., Schneider, J., Samols, E. and Mushmore, D.B. (1996) Glimepiride, a new once-daily sulfonylurea. Diabetes Care, 19, 1194-1199.
[3] Rosskamp, R., Wernicke-Panten, K. and Draeger, E. (1996) Clinical profile of the novel sulfonylurea glimepiride. Diabetes Research and Clinical Practice, 31, S33-S42.
[4] Inukai, K., Watanabe, M., Nakashima, Y., Sawa, T., Takata, N., Tanaka, M., Kashiwabara, H., Yokota, K., Suzuki, M., Kurihara, S., Awata, T. and Katayama, S. (2005) Efficacy of glimepiride in Japanese Type 2 diabetic subjects. Diabetes Research and Clinical Practice, 68, 250-257. 1016/j.diabres.2004.10.002
[5] Haupt, A., Kausch, C., Dahl, D., Bachmann, O., Stumvoll, M., Haring, H.U. and Matthaei, S. (2002) Effect of glimepiride on insulin-stimulated glycogen synthesis in cultured human skeletal muscle cells; a comparison to glibenclamide. Diabetes Care, 25, 2129-2132. 2004.10.002
[6] Muller, G. and Wied, S. (1993) The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation and dephosphorylation in insulin-resistant rat adipocytes in vitro. Diabetes, 42, 1852-1867.
[7] Inukai, K., Watanabe, M., Nakashima, Y., Takata, N., Isoyama, A., Sawa, T., Kurihara, S., Awata, T. and Katayama, S, (2005) Glimepiride Enhances Intrinsic Peroxisome Proliferator Activated Receptor-g Activity in 3T3-L1 Adipocytes. Biochemical and Biophysical Research Communications, 328, 484-490.
[8] Fukuen, S., Iwaki, M., Yasui, A., Makishima, M., Matsuda, M. and Shimomura, I. (2005) Sulphonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. The Journal of Biological Chemistry, 280, 23653-23659.
[9] Marco, S., Podvinec, M., Roth, A., Hug, H., Kersten, S., Albrecht, H., Schwede, T., Meyer, U.A. and Rücker, C. (2007) Sulphonylureas and glinide exhibit peroxisome prolierator-activated receptor g activity: A combined virtual screening and biological assay approach. Molecular Pharmacology, 71, 398-406.
[10] Müller, G., Hartz, D., Pünter, J., Okonomopulos, R. and Kramer, W. (1994) Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor I Binding characteristics. Biochimica et Biophysica Acta, 1192, 267-277.
[11] Rendell, M. (2004) The role of sulfonylurea in the management of Type 2 diabetes mellitus. Drugs, 64, 1339-1358.
[12] Feinb?ck, C., Luger, A., Klinger, A., Egger, T., Bielesz, G.K., Winkler, F., Siebenhofer, A., Grossch?dl, F., Frank, E. and Irsigler, K. (2003) Prospective multicentre trial comparing the efficacy of and compliance with, glimepiride or acarbose treatment in patients with Type 2 diabetes not controlled with diet alone. Diabetes, nutrition & metabolism, 16, 214-221.
[13] Korytkowski, M., Thomas, A., Reid, L., Tedesco, M.B., Gooding, W.E. and Gerich, L. (2002) Glimepiride improves both first and second phases of insulin secretion in Type 2 diabetes. Diabetes Care, 25, 1607-1611.
[14] Muller, G.., Satoy, Y. and Geisen, K. (1995) Extrapancreatic effects of sulfonylurea-A comparison between glimepiride and conventional sulfonylurea. Diabetes Research and Clinical Practice, 28, S115-S137.
[15] UK Prospective Diabetes Study Group (1995) Overview of 6 year’s therapy of Type 2 diabetes: A progressive disease. Diabetes, 44, 1249-1258.
[16] Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R. and Neil, H.A. (2008) 10-year follow-up of intensive glucose control in Type 2 diabetes. The New England Journal of Medicine, 359, 1577-1589.
[17] Miyauchi, H., Minamino, T., Tateno, K., Kunieda, T., Toko, H. and Komuro, I. (2004) Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/ p21-dependent pathway. The EMBO Journal, 23, 212-220.
[18] Sato, T., Nishida, H., Miyazaki, M. and Nakaya, H. (2006) Effects of sulfonylureas on mitochondrial ATP-sensitive K+ channels in cardiac myocytes: Implications for sulfonylurea controversy. Diabetes/Metabolism Research and Reviews, 22, 341-347.

comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.